Zacks Investment Management Iovance Biotherapeutics, Inc. Transaction History
Zacks Investment Management
- $10.5 Billion
- Q1 2025
A detailed history of Zacks Investment Management transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 13,200 shares of IOVA stock, worth $29,172. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,200Holding current value
$29,172% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding IOVA
# of Institutions
334Shares Held
247MCall Options Held
1.34MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA27.8MShares$61.4 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$54 Million12.15% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$46.9 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY12.7MShares$28.1 Million1.77% of portfolio
-
State Street Corp Boston, MA11MShares$24.4 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $349M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...